secwatch.observer — SEC 8-K summary
======================================

Issuer:     Denali Therapeutics Inc. (DNLI)
CIK:        0001714899
Form:       8-K
Filed at:   2025-07-07T23:59:59+00:00
Accession:  0001714899-25-000146
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA accepts Denali's BLA for tividenofusp alfa with Priority Review; PDUFA Jan 5, 2026
--------------------------------------------------------------------------------

- FDA grants Priority Review for BLA seeking accelerated approval of tividenofusp alfa for Hunter syndrome (MPS II).
- PDUFA target action date set for January 5, 2026.
- Tividenofusp alfa is designed to deliver IDS enzyme across the blood-brain barrier using TransportVehicle platform.
- BLA supported by Phase 1/2 data from 47 participants; ongoing Phase 2/3 COMPASS study for global approvals.
- If approved, would be first new enzyme replacement therapy for Hunter syndrome in nearly two decades.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1714899/000171489925000146/0001714899-25-000146-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1714899/000171489925000146/dnli-20250707.htm
  HTML page:      https://secwatch.observer/filing/0001714899-25-000146

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer